Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX6m plus monoclonal antibody with or without hepatic irinotecan chemoembolization for liver-limited metastatic colorectal cancer
2024-517782-16-00Phase 2Authorised
- Sponsor
- GEMCAD
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, bevacizumab, panitumumab, cetuximab, oxaliplatin and 2 more in colorectal cancer (CRC) (2 arms), sponsored by GEMCAD. Primary endpoint: Objective radiological response rate at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
irinotecanbevacizumabpanitumumabcetuximaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-517782-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517782-16-00.